Actively Recruiting
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
Led by Universitat Autonoma de Barcelona · Updated on 2024-05-23
160
Participants Needed
1
Research Sites
173 weeks
Total Duration
On this page
Sponsors
U
Universitat Autonoma de Barcelona
Lead Sponsor
P
Parc Sanitari Sant Joan de Déu
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery. The main questions it aims to answer are: * Does combined REHACOP + MCT therapy increase the clinical recovery in persons with nonaffective psychotic disorder (compared to MCT alone)? * What is the impact of combined REHACOP + MCT therapy compared to MCT therapy alone on personal/psychological recovery, cognitive biases, and social cognition, taking gender differences into account? * What is the durability of the effects of combined REHACOP + MCT therapy compared to MCT therapy alone on clinical recovery, personal recovery, cognitive biases, and social cognition in the long term? Researchers will compare REHACOP+MCT therapy to MCT alone to see if there are differences in personal/psychological recovery. Participants will: * Participate in Metacognitive Training or in combined REHACOP + Metacognitive training therapy. * Do 8 weekly sessions of 45-60 minutes (MCT group). * Do 12 weekly sessions of 45-60 minutes (RECHACOP+MCT group). * Visit the clinic for checkups and tests. * Answer self-administered tests.
CONDITIONS
Official Title
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of schizophrenia, schizophreniform disorder, delusional disorder, brief psychotic disorder, schizoaffective disorder, or other schizophrenia spectrum and psychotic disorders according to DSM-5
- Currently in a stable clinical phase with no psychiatric hospitalization in the last 3 months
- Good adherence to pharmacological treatment
- Cognitive impairment shown by T-score below 40 in specified cognitive tests (TAVEC, CPT-IP, TMT, Stroop, WSCT, FAS, WAIS subtests)
- Willingness to participate and provide signed informed consent
You will not qualify if you...
- History of traumatic brain injury, dementia, or intellectual disability with IQ below 70
- High scores on Positive and Negative Syndrome Scale indicating hostility, lack of cooperation, or suspiciousness
- Diagnosis of severe substance-related disorder
- Participation in Cognitive Remediation or Metacognitive Training therapy in the previous year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Universitat Autonoma de Barcelona
Cerdanyola del Vallès, Barcelona, Spain, 08193
Actively Recruiting
Research Team
A
Ana Barajas Velez
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here